Can I Take Resveratrol with Intrarosa (Prasterone Vaginal DHEA)?

What Is Intrarosa and Why Do Women Use It?

Intrarosa is the brand name for prasterone, a synthetic form of dehydroepiandrosterone (DHEA) delivered as a 6.5 mg vaginal insert used nightly. The FDA approved it in November 2016 for moderate-to-severe dyspareunia caused by genitourinary syndrome of menopause (GSM). GSM affects an estimated 27 to 84 percent of postmenopausal women, though many never report it to a clinician.

How Prasterone Works Locally

Unlike systemic hormone therapy, Intrarosa acts through a process called intracrinology. The prasterone molecule is taken up by vaginal epithelial cells and converted locally into both androgens (androstenedione, testosterone) and estrogens (estradiol, estrone) via enzymes including 3-beta-hydroxysteroid dehydrogenase and aromatase. This local conversion restores vaginal tissue without meaningfully raising circulating sex hormone levels.

The phase III ERC-238 trial showed that nightly 6.5 mg prasterone reduced dyspareunia severity scores significantly versus placebo, with serum estradiol and testosterone remaining within the expected postmenopausal reference range throughout the 12-week study. That systemic-sparing profile is part of why some clinicians favor it over topical estradiol in women who are cautious about any systemic hormonal exposure.

Who Typically Uses It

Women using Intrarosa are most often postmenopausal, between ages 50 and 70, and dealing with vaginal dryness, painful intercourse, or recurrent irritation that affects sexual health and quality of life. Some perimenopausal women with early GSM symptoms are also prescribed it off-label. The Menopause Society (formerly NAMS) 2023 position statement lists vaginal DHEA as an effective non-estrogen option for GSM.

What Is Resveratrol and Why Do Women Take It?

Resveratrol is a polyphenol found in grape skins, red wine, berries, and Japanese knotweed. Women take it for a range of reasons including cardiovascular protection, anti-aging, cognitive support, and, increasingly, menopausal symptom relief. Typical commercial supplements contain 100 to 500 mg per capsule, though doses in research trials have reached 1,000 to 1,500 mg per day.

Resveratrol's Estrogenic Activity: What the Science Actually Shows

This is the detail most supplement-review sites miss. Resveratrol is a phytoestrogen. It binds both estrogen receptor alpha (ER-alpha) and estrogen receptor beta (ER-beta) with a preference for ER-beta, the receptor subtype that tends to produce tissue-protective rather than proliferative effects. Its binding affinity is roughly 7,000-fold weaker than 17-beta-estradiol at ER-alpha.

At typical supplement doses, the estrogenic signal is small. A 2021 randomized trial in 70 postmenopausal women found that 150 mg/day of resveratrol for 12 weeks did not significantly change serum FSH, LH, estradiol, or SHBG compared to placebo, suggesting that the hormonal footprint at standard doses is modest. At higher doses (1,000 mg/day and above), some researchers have observed changes in sex-hormone-binding globulin, which can influence free androgen availability.

Resveratrol and Aromatase: A Potentially Relevant Pathway

Resveratrol has been shown in in vitro studies to inhibit aromatase (CYP19A1), the enzyme that converts androgens to estrogens. This is the same enzymatic pathway that prasterone relies on inside vaginal epithelial cells. The clinical significance of this overlap is unclear because the concentrations needed to inhibit aromatase meaningfully in cell culture are far above what typical oral resveratrol doses achieve in tissue. Still, the mechanistic overlap is worth understanding.

The Interaction Question: Pharmacokinetic or Pharmacodynamic?

Most women asking "can I take resveratrol with Intrarosa" are worried about a drug-drug interaction in the traditional sense. A pharmacokinetic interaction means one substance changes how the other is absorbed, distributed, metabolized, or excreted. A pharmacodynamic interaction means both substances act on the same biological pathway, amplifying or blunting each other's effects.

Is There a Pharmacokinetic Interaction?

Intrarosa is not metabolized through the cytochrome P450 system at the systemic level in any clinically meaningful way, because the conversion of DHEA to sex steroids happens inside vaginal tissue cells via hydroxysteroid dehydrogenases and aromatase, not via hepatic CYP enzymes. Resveratrol is a known inhibitor of CYP3A4 and CYP2C9 in vitro and at high doses can raise plasma levels of drugs metabolized by those enzymes. Because Intrarosa's systemic exposure is minimal, this CYP3A4 overlap is not expected to produce a clinically relevant pharmacokinetic interaction at standard resveratrol doses (100 to 500 mg/day).

No pharmacokinetic interaction study specific to this combination exists in the published literature as of July 2025. The Intrarosa prescribing information does not list resveratrol as a drug interaction, and resveratrol is not a prescription drug subject to formal interaction screening.

The Pharmacodynamic Question: Additive Estrogenic Activity

This is where the more realistic concern lives. Both prasterone (via local conversion to estradiol) and resveratrol (via weak ER binding) produce some degree of estrogen receptor signaling in tissues. In vaginal tissue specifically, the local estrogen from prasterone conversion is intentional and therapeutic. Resveratrol's contribution at standard doses would be small and likely clinically insignificant.

A useful clinical framework is to think in tiers:

Tier 1 (Low concern): Resveratrol 100 to 250 mg/day with nightly Intrarosa 6.5 mg. Systemic estradiol from Intrarosa remains in the postmenopausal range, and resveratrol's ER activity at this dose is minimal. No dose separation is required.

Tier 2 (Monitor): Resveratrol 500 mg/day or above. SHBG and free androgen levels may shift. Women with hormone-sensitive conditions (history of estrogen-receptor-positive breast cancer, for example) should discuss this tier with their oncologist before continuing either agent.

Tier 3 (Discuss proactively): Any dose in women with a personal history of ER-positive breast cancer, endometrial cancer, or a BRCA mutation. Intrarosa itself is not formally contraindicated in breast cancer survivors by all guidelines, but the ACOG Clinical Consensus on GSM in cancer survivors advises individualized risk-benefit discussion. Adding a phytoestrogen supplement to that picture adds a variable worth naming.

Sex-Specific Physiology: Why This Interaction Question Is Different for Women

Women metabolize and respond to both DHEA and resveratrol differently depending on their hormonal environment, and that environment shifts across reproductive life stages.

Reproductive Years

Women still having regular cycles have strong endogenous estrogen production. Adding vaginal prasterone in reproductive-age women is uncommon (it is FDA-approved for postmenopausal GSM), but it is occasionally used off-label. In cycling women, exogenous DHEA may alter the androgen-to-estrogen ratio locally and systemically in ways that are poorly studied. Resveratrol at higher doses has been studied in women with PCOS, where one randomized trial found 1,500 mg/day for three months reduced total testosterone and DHEAS while improving insulin sensitivity. If you have PCOS and are considering resveratrol, the hormonal effects at high doses are real and worth discussing with your clinician before combining it with any DHEA-containing product.

Perimenopause

Estrogen fluctuates widely in perimenopause, and FSH is not a reliable guide to menopausal status. Some perimenopausal women develop GSM symptoms before their final menstrual period. In this stage, adding weak estrogenic signals from resveratrol on top of locally delivered DHEA-derived estrogens is unlikely to cause harm, but there is no trial evidence specifically in perimenopausal women for this combination.

Post-Menopause

This is the population for whom Intrarosa is approved and most of the relevant pharmacology data exists. Serum estradiol in the postmenopausal range is typically below 20 pg/mL. The Labrie et al. 2016 study confirmed that 6.5 mg nightly prasterone did not push serum estradiol above 35 pg/mL in any participant over 12 weeks. Adding resveratrol 100 to 500 mg/day is not expected to materially change that picture.

Pregnancy, Lactation, and Contraception

Intrarosa is contraindicated in pregnancy. Prasterone is an androgen precursor, and androgenic exposure during pregnancy carries teratogenic risk, particularly for female fetal virilization. The FDA label classifies prasterone vaginal as contraindicated in pregnancy and states it should be discontinued if pregnancy is confirmed.

Resveratrol safety in pregnancy has not been established in controlled human trials. Animal studies using high-dose resveratrol have produced mixed results, including effects on fetal programming and placental function. The cautious clinical position is to avoid resveratrol supplementation during pregnancy. A 2019 review in Advances in Nutrition concluded that evidence is insufficient to support resveratrol use during pregnancy or lactation.

Lactation: There is no published data on prasterone vaginal transfer into breast milk, and breastfeeding is not a typical clinical scenario for GSM treatment. Resveratrol transfers into breast milk in animal models; human data are absent. Women who are breastfeeding should avoid both agents until more data exist.

Contraception: Because Intrarosa is a DHEA-derived product with androgen activity, women of reproductive age using it off-label should use effective contraception. No formal teratogen registry exists for prasterone vaginal, but the FDA label recommends discontinuation if pregnancy occurs.

Who Is This Combination Right For, and Who Should Think Twice?

Likely Fine to Continue Both

• Postmenopausal women taking Intrarosa nightly and resveratrol 100 to 250 mg/day for general cardiovascular or cognitive reasons.
• Women without a personal or strong family history of hormone-sensitive cancer.
• Women whose GSM symptoms are well-controlled on Intrarosa and who want to continue resveratrol for non-gynecologic reasons.

Discuss with Your Clinician First

• Women taking resveratrol at 500 mg/day or above, particularly those with elevated baseline androgens.
• Women who have or have had ER-positive breast cancer, endometrial hyperplasia, or endometrial cancer. The Menopause Society's guidance on breast cancer survivors and vaginal therapies emphasizes individualized shared decision-making, and a phytoestrogen supplement changes the conversation.
• Women with a BRCA1 or BRCA2 mutation who are taking prophylactic measures.
• Women with PCOS using prasterone off-label, given resveratrol's documented effect on androgens and SHBG at high doses as shown in the Banaszewska et al. 2016 trial.

Who Should Pause Resveratrol While Starting Intrarosa

No evidence requires a pause period. If you just started Intrarosa and are worried about the combination, the most pragmatic approach is to continue both at standard doses and reassess GSM symptoms at 8 to 12 weeks, which is the standard timeframe recommended in the Menopause Society's 2023 position statement for evaluating vaginal therapy response.

What to Monitor If You Are Taking Both

Routine serum hormone monitoring is not standard practice for women on Intrarosa alone, and adding resveratrol does not change that default recommendation for most postmenopausal women. The Labrie et al. Clinical pharmacology data showed stable hormone levels at the 6.5 mg dose, so the baseline monitoring bar is already low.

Pay attention to:

• Vaginal symptoms. If GSM symptoms worsen or new spotting appears, contact your prescriber.
• Breast tenderness. This can be an early sign of unexpected estrogenic stimulation; it warrants evaluation.
• Endometrial safety signals. Because Intrarosa delivers some local estrogen, women with an intact uterus should report any unexpected uterine bleeding promptly. The PRASTERONE-Endometrial Safety trial (ERC-238 substudy) showed no increase in endometrial thickness versus placebo over 12 weeks, which is reassuring, though long-term data beyond 52 weeks are limited.
• Resveratrol dose creep. Some women escalate supplement doses over time. Staying at or below 500 mg/day keeps the pharmacodynamic overlap manageable.

The Evidence Gap: What We Do Not Yet Know

Women have historically been underrepresented in pharmacology research, and the intersection of vaginal drug delivery with dietary supplement pharmacology is a particularly thin area of evidence. To be direct about what is extrapolated versus directly studied:

• Directly studied: Prasterone vaginal pharmacokinetics and serum hormone levels in postmenopausal women, from the PRASTERONE phase III program.
• Directly studied: Resveratrol estrogenic binding affinity and in vitro aromatase inhibition, from Gehm et al. 1997 and Maggiolini et al. 2001.
• Directly studied in women: Resveratrol 150 mg/day effect on serum hormones in postmenopausal women, from Wong et al. 2021.
• Extrapolated, not directly studied: Whether resveratrol at 100 to 500 mg/day meaningfully modulates the local intracrine conversion of prasterone in vaginal epithelium.
• Unknown: Long-term combined safety signal data for this specific combination in any population.

The honest answer is that no one has run the experiment. The absence of a known interaction is not the same as a confirmed clean safety record. That distinction matters for informed decision-making.

Practical Steps If You Are Already Taking Both

1. Note your doses. Write down the exact Intrarosa schedule (nightly versus every other night, if your prescriber has adjusted) and your resveratrol dose and brand.
2. Bring it to your next visit. Share this with your gynecologist or menopause specialist, specifically framing it as a question about additive estrogenic activity, not just a general supplement question.
3. Report new symptoms promptly. Uterine spotting, breast tenderness, or a return of GSM symptoms after initial improvement all warrant contact before your next scheduled visit.
4. Keep resveratrol at or below 500 mg/day if you choose to continue both, given the dose-dependent effects on SHBG and androgen metabolism observed at higher doses.
5. Reassess at 8 to 12 weeks. This aligns with the standard Intrarosa response window and gives you a natural checkpoint to evaluate whether anything has shifted.

The ACOG committee opinion on dietary supplements in women's health reinforces that "supplement" does not mean "inert," and that clinicians should ask proactively rather than waiting for patients to volunteer supplement use.